No material impact from DRL's Semaglutide supply delay, says OneSource
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Smallcap 250 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
OneSource Specialty Pharma clarifies that Dr. Reddy's Laboratories' delay in commercial supplies of Semaglutide has no material financial or operational impact on the company. OneSource, which is DRL's manufacturing partner for generic Semaglutide Injection, says it has enough demand from other customers including Canada, with capacities fully committed. It is adding new capacities this quarter and later in the year to meet all demand, including DRL's when ready.
Reassuring for investors; OneSource says the DRL delay does not affect financials, with alternative demand and capacity ready.